You Might Also Like
Also By This Author
- Novartis AG. News release: Novartis’ Cosentyx is first biologic to show long-term efficacy in nail and palmoplantar psoriasis, which can impact up to 90% of psoriasis patients. 2017 Nov 30.
The Foundation is the largest private funding source for rheumatology research and training in the U.S.
Learn more about the ACR’s public awareness campaign and how you can get involved. Help increase visibility of rheumatic diseases and decrease the number of people left untreated.